GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

  • Collaboration combines innovative plant-based and adjuvant technologies to develop and produce a COVID-19 candidate vaccine
  • Phase 1 clinical testing scheduled to begin mid-July
  • Collaboration to explore vaccine development opportunities for other infectious diseases

London and Quebec City - GSK and Medicago today announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. Use of an adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people. 

Pre-clinical results with Medicago’s CoVLP vaccine candidate demonstrated a high level of neutralizing antibodies following a single dose when administered with adjuvant.

Phase 1 clinical testing is planned to start in mid-July and will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSKs pandemic adjuvant and in parallel with an  adjuvant from another company, administered on a one- and two-dose vaccination schedule, given 21 days apart.

Subject to successful clinical development and regulatory considerations, the companies aim to complete development and make the vaccine available, in the first half of 2021. Both companies will also evaluate expanding their collaboration to develop a post-pandemic vaccine COVID-19 candidate, should the need arise based on the further development of COVID-19 after the pandemic, and other infectious diseases.

The companies will use Medicago’s plant-based production platform to manufacture the COVID-19 vaccine antigen. This innovative technology uses the leaves of a plant as bioreactors to produce the S-spike protein which self-assemble into VLPs for use in the CoVLP vaccine candidate. It is highly scalable and can support the production of large amounts of vaccine in a significantly shortened timeline. Using this technology combined with GSKs proprietary adjuvant system, the companies expect to be able to manufacture approximately 100m doses  by the end of 2021. By the end of 2023, a large-scale facility under construction in Quebec City, Canada, is expected to deliver up to 1 billion doses annually. The manufacturing platform has been used to produce a seasonal VLP flu vaccine and the license application is under review with the Canadian regulatory authority.

Dr Thomas Breuer, Chief Medical Officer, GSK Vaccines, said: “This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. If successful, it will be a meaningful contributor in the fight against COVID-19. We strongly believe that multiple vaccines are needed, including post-pandemic vaccines. This plant-based technology also shows promise beyond COVID-19 and has the potential to help prevent other infectious diseases.”

Dr Bruce Clark, President and CEO of Medicago, said: “We are about to begin clinical trials with our CoVLP vaccine candidate harnessing GSKs pandemic adjuvant technology against the virus that causes COVID-19. This collaboration with GSK gives us access to a proven adjuvant which could enhance the effectiveness of our candidate vaccine, and also to a depth of scientific experience to support our development efforts”

GSK and Medicago have entered into a binding agreement to develop and manufacture an adjuvanted COVID-19 vaccine. Medicago is a privately held company jointly owned by Mitsubishi Tanabe Pharma (MTPC) and Philip Morris International (PMI), with a shareholding ratio of 67:33, respectively. PMI has signalled that it is willing to evaluate offers for its shareholding from parties that may be better suited to help Medicago on the next phase of its journey and has initiated preliminary review to determine the optimal shareholding and governance structure for Medicago’s future success.

About Medicago

Medicago is a biopharmaceutical company headquartered in Quebec City, Canada. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. For more information please visit www.medicago.com

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and any impacts of the COVID-19 pandemic.

Medicago Enquiries:

English speaking

Alissa von bargen
+1 647 234 5975 (Quebec City)

French speaking

Marie-Pier Côté
+ 1 418 999 4847 (Quebec City)

GSK Media Enquiries:

UK Media enquiries:

Simon Steel
+44 (0) 20 8047 5502 (London)

Simon Moore
+44 (0) 20 8047 5502 (London)

US Media enquiries:

Kristen Neese
+1 804 217 8147 (Philadelphia)

Kathleen Quinn 
+1 202 603 5003 (Washington DC)

Canada Media enquiries:

+1 905-819-3363 (Mississauga)

+1 450-680-4812 (Laval)

Analyst/Investor enquiries:

Sarah Elton-Farr
+44 (0) 208 047 5194 (London)

Danielle Smith
+44 (0) 20 8047 0932 (London)

James Dodwell 
+44 (0) 20 8047 2406 (London)

Jeff McLaughlin 
+1 215 751 7002 (Philadelphia)

Frannie DeFranco
+1 215 751 4855 (Philadelphia)

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS